Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

Data de publicação:

Autores da FMUP

  • Marta Fernanda Reina Couto

    Autor

  • Janete Maria Quelhas Dos Santos

    Autor

  • Teresa Maria De Jesus Teixeira De Sousa

    Autor

Participantes de fora da FMUP

  • Pereira Terra, P
  • Silva Pereira, C
  • Albino Teixeira, A

Unidades de investigação

Abstract

Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient's inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.

Dados da publicação

ISSN/ISSNe:
1664-042X, 1664-042X

Frontiers in Physiology  Frontiers Media S.A.

Tipo:
Review
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 45

Citações Recebidas na Scopus: 72

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • inflammation; chronic heart failure (CHF); acute heart failure (AHF); cardiogenic shock (CS); inflammatory mediators; clinical trials; anti-inflammatory strategies

Financiamento

Proyectos asociados

Unresolved inflammation and endothelitis in severe COVID-19 patients: identification of risk stratification biomarkers and therapeutic targets. (severe COVID-19)

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Severe COVID-19) . FCT . 2020

Endocan: a novel biomarker for risk stratification, prognosis, and therapeutic monitoring in human cardiovascular and renal diseases

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Endocan) . 2020

Renal renin-angiotensin system activation in acute heart failure and its association with endothelial dysfunction, inflammation and oxidative stress.

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Renal) . 2021

Urinary cysteinyl leukotrienes as biomarkers of endothelial activation, inflammation and oxidative stress and their relationship with organ dysfunction in human septic shock

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação